Journal of Oncology 2021

3 papers
The 2021 edition of the Journal of Oncology featured research focused on non-small-cell lung cancer (NSCLC) and metastatic melanoma, with an emphasis on real-world clinical outcomes and diagnostic technology. Studies explored the efficacy and safety of targeted therapies, such as afatinib for patients with EGFR mutations, and evaluated survival rates in melanoma patients following the discontinuation of anti-PD-1 immunotherapy. A notable trend in the 2021 contributions was the application of computational methods to oncology. Researchers utilized deep learning models to predict EGFR mutation and PD-L1 expression status in NSCLC using computed tomography (CT) images. This work reflects an interest in non-invasive diagnostic tools to complement traditional clinical assessments. Key contributors to the year's publications included authors such as Changqie Pan, Hua Yang, and Anne Pham‐Ledard, whose work spanned meta-analyses and retrospective observational studies. These papers highlight a focus on integrating artificial intelligence with established therapeutic evaluations to refine patient management strategies.

Top Research Directions

The 14 research directions with Journal of Oncology 2021 papers, ranked by paper count, next to 2020. Share is the fraction of the edition’s papers in the direction.

#Direction20212020Share 2021Share 20202020 rank
1Accelerating Molecular Diagnostics and Genomic Surveillance1033.3%0.0%—
2Adaptive Treatment Regimens through Titration and Interval Scaling1033.3%0.0%—
3Bridging the Efficacy Effectiveness Gap with Real World Data1033.3%0.0%—
4Evaluating Clinical Outcomes Using Historical Patient Cohorts1033.3%0.0%—
5Generalizing Clinical Trial Findings to Real World Populations1033.3%0.0%—
6Gradient Weighted Class Activation Mapping1033.3%0.0%—
7Multimodal Fusion of Radiomics and Clinical Biomarkers1033.3%0.0%—
8Nonparametric Estimation of Time to Event Data1033.3%0.0%—
9Proportional Hazards Modeling for Survival Analysis1033.3%0.0%—
10Quantifying and Adjusting for Publication Bias1033.3%0.0%—
11Quantifying Relative Drug Efficacy Without Head-to-Head Trials1033.3%0.0%—
12Random Effects Models for Statistical Meta Analysis1033.3%0.0%—
13Sparse Feature Selection via L1 Regularization1033.3%0.0%—
14Standardized Frameworks for Tumor Response Assessment1033.3%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Oncology 2021 papers: a paper credits every institution named in its affiliations, once. 5 institutions share 3 credited papers.

#InstitutionPapersShare20202020 rank
1025020z88 133.3%0—
2Centre Hospitalier Universitaire de Bordeaux 133.3%0—
3Inserm 133.3%0—
4Sichuan University 133.3%0—
5Université de Bordeaux 133.3%0—

Download all institutions as CSV

About this data

Papers. Journal of Oncology 2021 lists 3 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2020 use shares, since the edition went from 1 to 3 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 3 of 3 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-18 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Oncology 2021”, https://lacuna.tiptreesystems.com/venue/journal-of-oncology/2021.

Impactful Papers

Papers from Journal of Oncology 2021 that shaped research clusters.

Influential

Papers

Title
Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images
Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence
Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study